229 related articles for article (PubMed ID: 35177078)
21. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
Front Immunol; 2021; 12():762989. PubMed ID: 34975854
[TBL] [Abstract][Full Text] [Related]
22. Dual-targeting of artesunate and chloroquine to tumor cells and tumor-associated macrophages by a biomimetic PLGA nanoparticle for colorectal cancer treatment.
Peng J; Zhou J; Sun R; Chen Y; Pan D; Wang Q; Chen Y; Gong Z; Du Q
Int J Biol Macromol; 2023 Jul; 244():125163. PubMed ID: 37270126
[TBL] [Abstract][Full Text] [Related]
23. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
[TBL] [Abstract][Full Text] [Related]
24. Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer.
Yu H; Zhu W; Lin C; Jia M; Tan X; Yuan Z; Feng S; Yan P
Biomater Sci; 2023 Dec; 12(1):116-133. PubMed ID: 37921708
[TBL] [Abstract][Full Text] [Related]
25. Metabolic reprogramming by dual-targeting biomimetic nanoparticles for enhanced tumor chemo-immunotherapy.
Zang S; Huang K; Li J; Ren K; Li T; He X; Tao Y; He J; Dong Z; Li M; He Q
Acta Biomater; 2022 Aug; 148():181-193. PubMed ID: 35649505
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
27. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
28. Dual "Unlocking" Strategy to Overcome Inefficient Nanomedicine Delivery and Tumor Hypoxia for Enhanced Photodynamic-Immunotherapy.
Li X; Jiang C; Jia X; Cao Y; Mao Y; Hao JN; Yang Y; Zhang P; Li Y
Adv Healthc Mater; 2023 Jan; 12(6):e2202467. PubMed ID: 36377480
[TBL] [Abstract][Full Text] [Related]
29. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
30. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
31. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
32. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
33. T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy.
Kang M; Hong J; Jung M; Kwon SP; Song SY; Kim HY; Lee JR; Kang S; Han J; Koo JH; Ryu JH; Lim S; Sohn HS; Choi JM; Doh J; Kim BS
Adv Mater; 2020 Oct; 32(39):e2003368. PubMed ID: 32812291
[TBL] [Abstract][Full Text] [Related]
34. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
Wang Y; Gao Z; Du X; Chen S; Zhang W; Wang J; Li H; He X; Cao J; Wang J
Biomater Sci; 2020 Sep; 8(18):5121-5132. PubMed ID: 32820750
[TBL] [Abstract][Full Text] [Related]
35. Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer.
Zhang N; Li J; Gao W; Zhu W; Yan J; He Z; Li L; Wu F; Pu Y; He B
Mol Pharm; 2022 Sep; 19(9):3439-3449. PubMed ID: 35994700
[TBL] [Abstract][Full Text] [Related]
36. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
37. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z
Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
[TBL] [Abstract][Full Text] [Related]
39. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.
Hsieh CH; Hsieh HC; Shih FS; Wang PW; Yang LX; Shieh DB; Wang YC
Theranostics; 2021; 11(14):7072-7091. PubMed ID: 34093872
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
Meng X; Wang J; Zhou J; Tian Q; Qie B; Zhou G; Duan W; Zhu Y
Acta Biomater; 2021 Jun; 127():266-275. PubMed ID: 33813091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
